News
- Algorithms
- Billing code
- Biomarker
- Cancer of Unknown Primary
- cfDNA
- DNA
- Education
- End of Treatment
- GENAYA project
- Hartwig Medical Database
- Hartwig Medical Foundation
- Innovation
- IT
- Lab process
- Learning healthcare system
- Molecular diagnostics
- OncoAct
- Participating hospitals
- Patients' stories
- Personalized treatment
- Quality
- Rare cancers
- Research
- Scientific publications
- Uncategorized
- Whole genome sequencing
- Working in the cloud
Unique insights in the differences between primary and metastatic cancer by large-scale DNA data analyses
Researchers have obtained valuable insights into the development of tumors from a unique Dutch data collection. These insights provide relevant …
Collaboration for future-proof diagnostics and to accelerate research
Complete analysis of the DNA of children with cancer offers many possibilities. It maps out all possible targeted treatment options …
22 impactful scientific publications in 2022
In 2022, research groups from all over the world published 22 scientific papers in which data from the Hartwig Medical …
Towards a learning healthcare system by broad collaboration
Developing a new drug is expensive and takes a long time. In addition, there is only a slim chance that …
Unraveling of genetic mechanism behind tumor formation may improve targeted treatment for cancer patients
Genetic alterations in the FGFR2 gene occur in various cancer types and represent a promising target for therapies. However, clinical …
Whole genome sequencing is reliable, has added value, and can be embedded perfectly into everyday pathology diagnostics
Source: website Netherlands Cancer Institute With the rapidly expanding tableau of (increasingly tumor-agnostic) targeted therapies, genome-driven cancer care has become …
Prince Constantijn of the Netherlands chairman of the Hartwig Medical Foundation Supervisory Board
On July 14, Prince Constantijn of the Netherlands succeeded Robbert Dijkgraaf as chairman of the Supervisory Board of Hartwig Medical …
Growth Fund invests 325 million euros in Oncode-PACT to accelerate the development of cancer drugs
The National Growth Fund invests 325 million euros in the Oncode-PACT plan to accelerate the preclinical development process of cancer …
In the media: Rarity – Personalised cancer treatment – fact not fiction
Imagine a world in which each person’s cancer is treated with a personalised, targeted medical treatment regimen. A world in …
Complete DNA analysis for young adults with cancer
KWF finances the expansion of the infrastructure for cancer research in young adults with almost 4.5 million euros. These are …
Single WGS analysis of metastases is sufficient in most cases
DNA analysis of the tumor is of crucial importance to determine treatment options for patients with metastasized lung cancer. But …
Actionable metastatic cancer genome is remarkably stable over time, despite treatment with drugs
A one-time analysis of the entire tumor DNA is almost always sufficient to find all DNA errors that may be …
Blogs
Cancer, a rare disease?
It may come as a surprise to many on this International Rare Disease Day (February 28), that a significant number …
Read more
The big advantage of having Hartwig Medical Foundation data available in the cloud
I don’t remember exactly when I first heard about Hartwig Medical Foundation and the whole genome sequencing data it has …
Read moreVideos
From biopsy to patient report
The comprehensive DNA test can provide patients with cancer with more opportunities for treatment. Using the technique of Whole Genome …
Read more
What does Hartwig Medical Foundation do?
Hartwig Medical Foundation is a unique initiative that makes possible progress in the research of treatment of cancer in the …
Read more
It is important to unravel the DNA in rare types of cancer; 21% of patients with cancer have a rare form.